Overview

This trial is active, not recruiting.

Condition prostate cancer
Treatments integrated imaging high intensity focused ultrasound, endocare cryocare cryosurgical and galil medical cryo-hit systems (cryotherapy)
Phase phase 2/phase 3
Sponsor EDAP TMS S.A.
Start date April 2006
End date August 2012
Trial size 141 participants
Trial identifier NCT00295802, G050103

Summary

The purpose of this study is to determine the substantial equivalence of the Ablatherm high intensity focused ultrasound (HIFU) as compared to cryotherapy for the treatment of low risk, localized prostate cancer.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation non-randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
Integrated Imaging High Intensity Focused Ultrasound using the Ablatherm Device
integrated imaging high intensity focused ultrasound HIFU
(Active Comparator)
Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)
endocare cryocare cryosurgical and galil medical cryo-hit systems (cryotherapy) Endocare CRYOcare Cryosurgical
Cryotherapy

Primary Outcomes

Measure
Attainment achievement of prostate-specific antigen (PSA) nadir < 0.5 ng/ml and stability of PSA according to American Society for Therapeutic Radiology and Oncology (ASTRO) criteria through 24 month follow up without a positive biopsy
time frame: Through 24 month period

Secondary Outcomes

Measure
Achievement of a nadir PSA within 6 months < 0.5 ng/ml
time frame: 6 months
Overall survival, defined as time to death due to any cause
time frame: From date of treatment until the date of death due to any cause
Disease specific survival, defined as the time to death due to the underlying disease
time frame: "From date of treatment until the date of death due to the underlying cause
Change from baseline in the University of California, Los Angeles Quality of Life (UCLA QOL)
time frame: 1 month, 6 months, 12 months, 24 months
Change from baseline in the International Prostate Symptom Score (IPSS)
time frame: 1 month, 6 months, 12 months, 24 months

Eligibility Criteria

Male participants at least 50 years old.

Inclusion Criteria: - Diagnosis of prostate cancer confirmed by PSA and prostate biopsy - Male subjects, aged equal to or over 50 years - Organ-confined prostate cancer, clinical stage T1a, b, or c or T2a - At least one positive biopsy within the previous 6 months - PSA equal to or less than 10 ng/ml - Gleason score equal to or less than 6 - Histological grading of 3+3, 3+2, 2+3, 2+4, or 2+2 based upon the baseline transrectal ultrasound (TRUS)-guided 10 core biopsy results. A subject with a histological grading of primary 4 will not be permitted for study enrollment. - Prostate volume equal to or less than 40 cc - Prostate anteroposterior (AP) diameter equal to or less than 25 mm - Normal rectal anatomy and rectal mucosa - Maximum rectal wall measurement 6 mm - The Investigator has completed a medical history and a physical examination to assure that the subjects meet all study enrollment criteria - The subject is willing and able to read, understand, and sign the study specific informed consent form - The subject agrees to comply with study protocol requirements, including HIFU or cryotherapy treatment and all follow up visit requirements through 24 months of follow up treatment. Exclusion Criteria: - Evidence of seminal vesicle involvement - Evidence of lymph node involvement or metastasis - Any previous treatment for prostate cancer including: external beam radiation therapy (EBRT), hormone therapy and/or previous bilateral orchiectomy - Previous surgery or procedure of the prostate (except prostate biopsy) or urethra within the prior one year - Calcification inducing a shadow in the prostate which cannot be included in the targeted volume - Large median lobe of the prostate which cannot be included in the target volume - Use within the previous 2 months of finasteride - Previous rectal surgery (other than hemorrhoidectomy) or history of rectal disease - Active inflammatory bowel syndrome - Current superficial bladder cancer, urethral stricture, or bladder neck contracture - Active urinary tract infection or prostatitis (the subject may be enrolled once the infection has been treated and has resolved) - Compromised renal function or upper urinary tract disease as a result of urinary obstruction - A history of bleeding disorders/coagulopathy or ongoing treatment for this condition - Urinary tract or rectal fistula - Rectal fibrosis, rectal stenosis, or other anomalies making the Ablatherm Integrated Imaging rectal probe insertion difficult - Anatomical anomaly of the rectum or anomaly of the rectal mucous membrane - Prostate seroma, prostate abscess, or urethral stenosis - An intraprostatic implant such as a stent or catheter, or any implant or prosthesis at less than 1 cm from the prostate - Interest in future fertility - Concurrent illness, disability, or geographical residence would hamper attendance at required study visits - Known latex hypersensitivity - Current participation in another clinical investigation of a medical device or a drug or has participated in such a study within 30 days prior to study enrollment - The Investigator believes that the subject will be unwilling or unable to comply with study protocol requirements, including the HIFU or cryotherapy procedure and study-related follow up visit requirements.

Additional Information

Official title Ablatherm Integrated Imaging High Intensity Focused Ultrasound for the Indication of Low Risk, Localized Prostate Cancer
Principal investigator Carey Robertson, MD
Description Primary hypothesis of this clinical investigation is that HIFU with the Ablatherm Integrated Imaging is non-inferior to minimally invasive cryosurgery as an effective treatment method for low risk, localized prostate cancer.
Trial information was received from ClinicalTrials.gov and was last updated in February 2014.
Information provided to ClinicalTrials.gov by EDAP TMS S.A..